TEGA Therapeutics, Inc.
TEGA Therapeutics was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. The company specializes in glycans, complex carbohydrates that play important roles in physiological and pathophysiological processes. TEGA's pipeline includes recombinant production of heparan sulfate and enzyme replacement therapy to treat genetic deficiencies in degradation of heparan sulfate, aiming to develop therapies for lysosomal storage disorders and other related diseases.
Industries
Nr. of Employees
small (1-50)
TEGA Therapeutics, Inc.
La Jolla, California, United States, North America
Products
Recombinant heparan sulfate reagent series (rHS variants)
A catalog of recombinant heparan sulfate/glycosaminoglycan variants produced in mammalian cell culture with defined molecular weights, sulfate contents and functional properties; available in single-milligram units and sampler/combo packs for research use.
Recombinant heparan sulfate reagent series (rHS variants)
A catalog of recombinant heparan sulfate/glycosaminoglycan variants produced in mammalian cell culture with defined molecular weights, sulfate contents and functional properties; available in single-milligram units and sampler/combo packs for research use.
Services
Commercial supply of recombinant heparan sulfate research reagents
Sale and distribution of multiple characterized recombinant heparan sulfate variants and sampler/combo packs for research use; products shipped as lyophilized powders with stated lead times and shipping options.
Collaborative preclinical R&D in glycoscience
In-house development of recombinant glycosaminoglycans and enzyme replacement therapy approaches; grant-supported projects and scientific publications indicate capacity for preclinical collaboration or research partnerships.
Commercial supply of recombinant heparan sulfate research reagents
Sale and distribution of multiple characterized recombinant heparan sulfate variants and sampler/combo packs for research use; products shipped as lyophilized powders with stated lead times and shipping options.
Collaborative preclinical R&D in glycoscience
In-house development of recombinant glycosaminoglycans and enzyme replacement therapy approaches; grant-supported projects and scientific publications indicate capacity for preclinical collaboration or research partnerships.
Expertise Areas
- Glycobiology research
- Recombinant glycosaminoglycan production
- Metabolic engineering of mammalian cells
- Enzyme replacement therapy development for lysosomal storage disorders
Key Technologies
- Metabolic engineering of mammalian cells
- Multiplex genome editing
- Mammalian cell culture biomanufacturing
- Recombinant glycosaminoglycan synthesis